Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.

You may also be interested in...



Antiplatelets In The Wilderness After Mixed Results From DAPT Study

FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.

Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics

Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.

High Hopes For Stent Antiplatelet Therapy Trial

FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel